After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
Ikena, Senti and others look to clinical presentations at AACR.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
